In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 7, 1997, Pages 1607-1608

  Meyer, Joette M ^a   Ryu, Seonyoung ^a   Pendland, Susan L ^a   Danziger, Larry H ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 HYDROXYCLARITHROMYCIN; AMOXICILLIN; BISMUTH SALICYLATE; CLARITHROMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; HELICOBACTER PYLORI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0030814013     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.7.1607     Document Type: Article

References (13)

1. Cederbrant, G., G. Kahlmeter, C. Schalen, and C. Kamme. 1994. Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxicillin, metronidazole, or omeprazole against Helicobacter pylori. J. Antimicrob. Chemother. 34:1025-1029.
2. Eliopoulos, G. M., and R. C. Moellering, Jr. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Williams Co., Baltimore, Md.
3. Goodwin, C. S., P. Blake, and E. Blincow. 1986. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J. Antimicrob. Chemother. 17:309-314.
4. Hardy, D. J., C. W. Hanson, D. M. Hensey, J. M. Beyer, and P. B. Fernandes. 1988. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J. Antimicrob. Chemother. 22:631-636.
5. Hardy, D. J., R. N. Swanson, R. A. Rode, K. Marsh, N. L. Shipowitz, and J. J. Clement. 1990. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxyclarithromycin, its major metabolite in humans. Antimicrob. Agents Chemother. 34:1407-1413.
6. Hoover, W. W., M. S. Barrett, and R. N. Jones. 1992. Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin. Diagn. Microbiol. Infect. Dis. 15:259-266.
7. Nagate, T., K. Numata, K. Handad, and I. Kondo. 1990. The susceptibility of Campylobacter pylori to antiulcer agents and antibiotics. J. Clin. Gastroenterol. 12(Suppl. 1):S135-S138.
8. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. Approved standard, NCCLS document M7-A3, vol. 13, no. 25. National Committee for Clinical Laboratory Standards, Villanova, Pa.
9. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. 1994. Helicobacter pylori in peptic ulcer disease. JAMA 272:65-69.
10. Pendland, S., S. Martin, C. Chen, P. Schreckenberger, and L. Danziger. 1994. In vitro activity of clarithromycin and its 14-hydroxymetabolite alone and in combination against 23 clinical isolates of Legionella, abstr. 138, p. 27. In Program and abstracts of the 2nd Annual Conference on the Macrolides, Azalides and Streptogramins, Venice, Italy.
11. Soll, A. H., for the Practice Parameters Committee of the American College of Gastroenterology. 1996. Medical treatment of peptic ulcer disease. Practice guidelines. JAMA 275:622-629.
12. Van Caekenberghe, D. L. V., and J. Breyssens. 1987. In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori). Antimicrob. Agents Chemother. 31:1429-1430.
13. Vogt, K., M. Warrelmann, and H. Hahn. 1989. The minimum inhibitory concentrations of various bismuth salts against Campylobacter pylori. Zentralbl. Bakteriol. 271:304-310.